Webcast overview
Companies in the Life Sciences industry have recently announced the intent to invest in excess of $500 billion in U.S. manufacturing, driven by supply chain resilience, and evolving policy considerations. While some organizations have committed capital and even have broken ground, many are still evaluating potential options and seeking input on how to optimize their ROI on this significant capital outlay.
KPMG Life Sciences Tax professionals will walk through the manufacturing lifecycle from a tax planning perspective, highlighting where opportunities and risks most often arise and how tax considerations influence site selection, incentives, capitalization, and value chain alignment.
